Characteristics of patients undergoing allo-HSCT
| Characteristic . | Median (range) or N (%) . |
|---|---|
| Age, y | 28 (8-61) |
| Sex | |
| Male | 24 (53) |
| Female | 21 (47) |
| Original disease | |
| AML | 17 (38) |
| ALL | 10 (22) |
| MDS | 4 (9) |
| NHL | 6 (13) |
| AA | 3 (7) |
| Others | 5 (11) |
| HSCT conditioning | |
| CY/TBI–based MAC | 18(40) |
| BU/CY–based MAC | 6 (13) |
| Other MAC | 5 (11) |
| FLU/MEL–based RIC | 3 (7) |
| FLU/BU–based RIC | 4 (9) |
| Other RIC | 3 (7) |
| Unknown | 6 (13) |
| HSCT donor | |
| rBM | 10 (22) |
| rPB | 13 (29) |
| uBM | 14 (31) |
| CB | 5 (11) |
| HaploBM | 3 (7) |
| Years from HSCT to development of pulmonary GVHD | |
| <1 y | 20 (44) |
| 1-3 y | 13 (29) |
| >3 y | 12 (27) |
| Years from HSCT to lung transplant | |
| 1-5 y | 19 (42) |
| 5-10 y | 13 (29) |
| >10 y | 13 (29) |
| Characteristic . | Median (range) or N (%) . |
|---|---|
| Age, y | 28 (8-61) |
| Sex | |
| Male | 24 (53) |
| Female | 21 (47) |
| Original disease | |
| AML | 17 (38) |
| ALL | 10 (22) |
| MDS | 4 (9) |
| NHL | 6 (13) |
| AA | 3 (7) |
| Others | 5 (11) |
| HSCT conditioning | |
| CY/TBI–based MAC | 18(40) |
| BU/CY–based MAC | 6 (13) |
| Other MAC | 5 (11) |
| FLU/MEL–based RIC | 3 (7) |
| FLU/BU–based RIC | 4 (9) |
| Other RIC | 3 (7) |
| Unknown | 6 (13) |
| HSCT donor | |
| rBM | 10 (22) |
| rPB | 13 (29) |
| uBM | 14 (31) |
| CB | 5 (11) |
| HaploBM | 3 (7) |
| Years from HSCT to development of pulmonary GVHD | |
| <1 y | 20 (44) |
| 1-3 y | 13 (29) |
| >3 y | 12 (27) |
| Years from HSCT to lung transplant | |
| 1-5 y | 19 (42) |
| 5-10 y | 13 (29) |
| >10 y | 13 (29) |
AA, aplastic anemia; AML, acute myeloid leukemia; ALL, acute lymphoid leukemia; BM, bone marrow; BU, busulfan; CB, cord blood; FLU, fludarabine; Haplo, haploidentical; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MEL, melphalan; NHL, non-Hodgkin lymphoma; PB, peripheral blood; r, related; RIC, reduced-intensity conditioning; u, unrelated.